AbbVie Inc (NYSE:ABBV) has announced new data from a Phase 2 trial of navitoclax combined with ruxolitinib in myelofibrosis patients at the American Association for Cancer Research annual meeting.
- The results presented at AACR 2022 were from REFINE Phase 2 trial, which included patients with myelofibrosis who had progressed on or had a suboptimal response to at least 12 weeks of ruxolitinib monotherapy.
- In the exploratory analysis of 32 evaluable patients, 12 (38%) had a ≥1 grade improvement in bone marrow fibrosis (BMF).
- For driver gene variant allele frequency (VAF) reduction, 26 patients were evaluable, and 6 (23%) achieved a ≥20% reduction at week 24.
- Five patients achieved both BMF and VAF responses.
- Median overall survival (OS) for all patients was not reached.
- For patients who had a ≥1 grade improvement, BMF median OS was not reached compared with 28.5 months for patients who did not experience an improvement.
- Similarly, median OS was also not reached for patients who achieved a ≥20% driver gene VAF reduction versus 28.5 months for patients who did not.
- All 34 patients (100%) experienced at least one adverse event (AE), and 15 (44%) experienced a serious adverse event (SAE).
- Price Action: ABBV shares are down 0.11% at $169.85 during the market session on the last check Tuesday.
